Edgar Filing: bluebird bio, Inc. - Form 4

bluebird bio	, Inc.										
Form 4 May 18, 202	16										
								OMB APPROVAL			
	UNITED	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								3235-0287	
Check th if no lon subject to Section Form 4 Form 5 obligation may con <i>See</i> Instr 1(b).	nger 50 16. 50 Filed put 50 50 50 50 50 50 50 50 50 50	Washington, D.C. 20549 Number: 5255-0207 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: January 31, 2005 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Expires: 2005 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, 0.5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 0.5									
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Davidson David			2. Issuer Name and Ticker or Trading Symbol bluebird bio, Inc. [BLUE]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (Middle) 3	3. Date of	f Earliest T	ransactior	1		(Check	all applicable)	
C/O BLUEBIRD BIO, INC., 150 SECOND STREET			(Month/Day/Year) 05/16/2016					Director 10% Owner X Officer (give title Other (specify below) Chief Medical Officer			
				. If Amendment, Date Original iled(Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
								Person			
(City)	(State)	(Zip)	Tabl	e I - Non-l	Derivativ	e Secu	rities Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemee Execution I any (Month/Day	Date, if	3. Transactic Code (Instr. 8) Code V	omr Dispo (Instr. 3,	sed of 4 and (A) or		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	05/16/2016			М	1,000	A	\$ 2.09	10,600	D		
Common Stock	05/16/2016			S <u>(1)</u>	1,000	D	\$ 38.7293 (2)	9,600	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: bluebird bio, Inc. - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number onof Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration E (Month/Day	Date	7. Title and Underlying a (Instr. 3 and	Securities	8. H Der Sec (In:
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.09	05/16/2016		М	1,000	(3)	04/13/2022	Common Stock	1,000	

Reporting Owners

Reporting Owner Name / Address	Relationships						
1	Director	10% Owner	Officer	Other			
Davidson David C/O BLUEBIRD BIO, INC. 150 SECOND STREET CAMBRIDGE, MA 02141			Chief Medical Officer				
Signatures							

Date

/s/Jason F. Cole,	05/18/2016
Attorney-in-Fact	05/16/2010

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). **
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, (1) 2015.
- The range of prices for the transaction reported on this line was \$38.37 to \$39.02. The average weighted price was \$38.7293. The (2) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option vests over a four-year period, at a rate of twenty-five percent (25%) on February 13, 2013 and in 36 equal monthly (3) installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.